Elbrit Life Sciences has announced a $2 million investment in setting up of its second manufacturing facility in Singtam, East Sikkim.Elbrit Life Sciences currently owns a manufacturing facility in Pondicherry with a capacity to manufacture 2 million units of solid dosage formulations per day.

 

The new facility in Sikkim will have a production capacity of 4 million units per day. The proposed facility will be UKMHRA and EUGMP complaint. Elbrit says that the plant will majorly focus on manufacturing finished solid dosage formulations for its domestic business as well as export business. Elbrit Life Sciences chose Sikkim its destination for its upcoming facility because of its emergence as a leading hub for pharmaceutical manufacturing, favourable geographical conditions, availability of skilled manpower and excellent co-operation from the state government.

 

The firm currently manufactures and markets a wide range of branded formulations across India with a major focus on cardiovascular, anti-diabetic and neurology range and overseas markets with a major focus on nutraceuticals. The company exports a wide range of nutraceutical products to South East Asia, Russia and Latin American countries. As the company looks to set a strong foothold in the domestic market and in the international market, the new facility will play a vital part in the company’s growth story.

 

The company’s new manufacturing facility in Sikkim is expected to generate direct employment for at least 250 people. The company aims the second manufacturing facility to be operational by mid of 2020 and expects the regulatory approvals to be completed by 2021.The new facility will help the company to expand its global footprint both in nutraceutical and pharmaceutical segments.Elbrit Life Sciences is looking to diversify into Oncology, Gynaecology, Paediatrics and Critical Care Nutraceuticals in the first half of next fiscal.

The new facility in Sikkim will have a production capacity of 4 million units of solid dosage formulations per day.